What is the 13F Pro Quality Score for AMGN?

13F Pro ranks AMGEN INC (AMGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMGN's current score at https://13fpro.ai/company/AMGN (free sign-up required for the full ranking).

Which hedge funds own the most AMGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AMGN include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/AMGN as soon as new 13F filings post.

Where does 13F Pro source AMGN data?

All AMGEN INC fundamentals and ownership data come directly from SEC EDGAR. AMGEN INC files with the SEC under CIK 318154. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMGN in?

AMGEN INC (AMGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives AMGN's revenue?

Per AMGEN INC's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Product sales ($9,537M, +9% YoY); Other revenues ($517M, +27% YoY); Repatha ($953M, +37% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/AMGN.

What are AMGN's largest expenses?

AMGEN INC's latest 10-Q reports these as the largest expense items: Cost of sales ($2,811M, -7% YoY); Research and development ($1,868M, +7% YoY); Selling, general and administrative ($1,745M, +3% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is AMGN research updated on 13F Pro?

AMGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AMGEN INC(AMGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmega

Institutional-grade research for retail investors

SEC EDGAR: CIK 318154 AMGN stock profile & AI dashboard →

13F Pro Quality Score

79.2/100

Rank #43 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

67.6/100

Profitability

85.6/100

Balance Sheet

84.5/100

Earnings Quality

72.5/100

Free Cash Flow

80.4/100

Institutional Flow

76.1/100

Revenue Scale

95.9/100

Dilution Risk

49.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AMGN Scores 79/100

exact factor attribution · 2026-09-11

AMGN's composite is driven by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.9 pts

96th pct

Profitability

+5.3 pts

86th pct

Free cash flow

+4.6 pts

80th pct

Revenue growth

+3.5 pts

68th pct

Capital efficiency

+3.5 pts

85th pct

Earnings quality

+2.3 pts

73th pct

Earnings growth

+1.9 pts

88th pct

Institutional flow

+1.3 pts

76th pct

Shareholder dilution

-0.1 pts

49th pct

Latest change (2026-08-07): 80 → 76 · ↓ Revenue growth 73→53; despite ↑ Earnings growth 67→79

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AMGN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for AMGEN INC (AMGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMGN at 79.2/100 on a 32-signal composite quality model, placing it at rank #43 of 2,961 stocks — the top 5% of the AI-ranked universe. AMGN scores in the top quartile across revenue scale (95.9), profitability (85.6), balance sheet strength (84.5). Shareholder dilution risk is elevated at 49.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AMGEN INC reports quarterly revenue of $10.1B, net income of $2.4B, an operating margin of 34.9%. Top institutional holders of AMGN by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. AMGN trades on the Nasdaq exchange and files with the SEC under CIK 318154. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMGEN INC directly from SEC EDGAR. AMGEN INC's 13F Pro composite quality score has ranged between 65 and 81 since 2021, currently 79.2 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about AMGEN INC

Quirks, history, and lore behind AMGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue around $33 billion, with a fat profit margin north of 25% — this is not a company that sells aspirin at Walgreens.
3
The History
Founded in 1980 as one of the first-ever biotechnology companies, it pioneered turning living cells into blockbuster medicines instead of old-school chemistry.
4
The Secret
Its early success was built on drugs that help the body make red blood cells and fight infections after chemotherapy — not glamorous, but worth billions.
5
The Lore
Its hit drug Enbrel — for rheumatoid arthritis — was once among the best-selling drugs on Earth, and the company has long been the quiet giant that other biotech firms dream of becoming.
6
The Giveaway
The granddaddy of Thousand Oaks biotech, its name is a mashup of "applied molecular genetics" — and yes, that's basically their whole elevator pitch since 1980.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving AMGN's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from AMGEN INC's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues rose 10% to $10,054M as volume-driven growth in Repatha, EVENITY, UPLIZNA and TEZSPIRE outweighed biosimilar erosion in Prolia and XGEVA; net income rose 66% to $2,375M.

Biggest Revenue Drivers

Product sales$9,537M+9% YoY

Increase driven by volume growth; U.S. volume grew 9% and ROW volume grew 8%

Other revenues$517M+27% YoY

Driven by higher corporate partner revenue and royalty income

Biggest Revenue Drivers

Total revenue: $10,054M+10% YoY

Product sales$9,537M+9% YoY

Increase driven by volume growth; U.S. volume grew 9% and ROW volume grew 8%

Within Product sales

Repatha$953M+37% YoY

Driven by volume growth

Prolia$759M-32% YoY

Lower volume of 20% and lower net selling price of 12% amid multiple biosimilar launches

EVENITY$714M+38% YoY

Driven by volume growth

Other revenues$517M+27% YoY

Driven by higher corporate partner revenue and royalty income

Largest Expense Items

Cost of sales$2,811M-7% YoY

Lower amortization from acquisition-related assets, partly offset by higher profit share expense, manufacturing costs and sales mix

Research and development$1,868M+7% YoY

Higher spend in Later-Stage Clinical Programs, primarily MariTide, and Marketed Product Support

Selling, general and administrative$1,745M+3% YoY

Higher general and administrative expenses and higher commercial product-related expenses

Other operating expenses$116M+51% YoY

Included litigation expenses and settlements

Margins: Cost of sales fell to 28.0% of total revenues from 32.8%, driven by lower acquisition-related amortization, partly offset by higher profit share, manufacturing costs and sales mix; operating income rose 32%.

Watch Items from the Filing

IRS disputes seek additional federal tax of ~$3.6B (2010–2012) and ~$5.1B plus ~$2.0B penalties (2013–2015); a new 2016–2018 NOPA was reissued in July 2026.
FDA proposed withdrawing TAVNEOS approval; related developed-product-technology rights carry $2.4B, with $2.3B tied to the U.S. market.
Prolia fell 32% and XGEVA fell 34%; company expects accelerated erosion for the remainder of 2026 as biosimilars launch in the U.S. and ROW.
ENBREL net selling price fell 22% from U.S. Medicare Part D price setting effective January 1, 2026; Otezla price setting begins January 2027.
BeOne equity stake (~17%) valued at $5.4B produced a $227M unrealized loss in the quarter, recorded in other expense.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$10.1B

Net Income

Q2 2026

$2.4B

Free Cash Flow

Q2 2026

$3.5B

Operating Margin

Q2 2026

34.9%

ROIC

Q2 2026

18.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.0% YoY

$36.75BFY 2025

FY22 $26.32BFY23 $28.19BFY24 $33.42BFY25 $36.75B

Net Income

+88.5% YoY

$7.71BFY 2025

FY22 $6.55BFY23 $6.72BFY24 $4.09BFY25 $7.71B

Operating Income

+25.1% YoY

$9.08BFY 2025

FY22 $9.57BFY23 $7.90BFY24 $7.26BFY25 $9.08B

EPS (Diluted)

+88.2% YoY

$14.23FY 2025

FY22 $12.11FY23 $12.49FY24 $7.56FY25 $14.23

Total Assets

-1.4% YoY

$90.59BFY 2025

FY22 $65.12BFY23 $97.15BFY24 $91.84BFY25 $90.59B

Total Debt

-7.0% YoY

$59.20BFY 2025

FY22 $40.54BFY23 $66.06BFY24 $63.65BFY25 $59.20B

Op. Cash Flow

-13.3% YoY

$9.96BFY 2025

FY22 $9.72BFY23 $8.47BFY24 $11.49BFY25 $9.96B

Free Cash Flow

-22.1% YoY

$8.10BFY 2025

FY22 $8.79BFY23 $7.36BFY24 $10.39BFY25 $8.10B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$36.75B +10.0%	$33.42B +18.6%	$28.19B +7.1%	$26.32B +1.3%	$25.98B +2.2%	$25.42B
Net Income	$7.71B +88.5%	$4.09B -39.1%	$6.72B +2.5%	$6.55B +11.2%	$5.89B -18.9%	$7.26B
Operating Income	$9.08B +25.1%	$7.26B -8.1%	$7.90B -17.4%	$9.57B +25.2%	$7.64B -16.4%	$9.14B
EPS (Diluted)	$14.23 +88.2%	$7.56 -39.5%	$12.49 +3.1%	$12.11 +17.8%	$10.28 -16.5%	$12.31
Total Assets	$90.59B -1.4%	$91.84B -5.5%	$97.15B +49.2%	$65.12B +6.5%	$61.16B -2.8%	$62.95B
Total Debt	$59.20B -7.0%	$63.65B -3.6%	$66.06B +63.0%	$40.54B +21.4%	$33.40B +1.0%	$33.08B
Operating Cash Flow	$9.96B -13.3%	$11.49B +35.6%	$8.47B -12.9%	$9.72B +5.0%	$9.26B -11.8%	$10.50B
Free Cash Flow	$8.10B -22.1%	$10.39B +41.2%	$7.36B -16.2%	$8.79B +4.8%	$8.38B -15.2%	$9.89B

Get alerted when AMGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AMGEN INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMGN

BlackRock, Inc.
$17.9B49,362,016 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.8B35,250,101 sh
STATE STREET CORP
$11.1B30,560,537 sh
Capital World Investors
$10.5B29,075,329 sh
Invesco Ltd.
$5.9B16,320,446 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.7B15,696,068 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$5.4B15,034,038 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.4B14,853,366 sh
MORGAN STANLEY
$4.9B13,653,692 sh
WELLS FARGO & COMPANY/MN
$2.6B7,235,462 sh

Fund	Value	Shares
BlackRock, Inc.	$17.9B	49,362,016
VANGUARD CAPITAL MANAGEMENT LLC	$12.8B	35,250,101
STATE STREET CORP	$11.1B	30,560,537
Capital World Investors	$10.5B	29,075,329
Invesco Ltd.	$5.9B	16,320,446
GEODE CAPITAL MANAGEMENT, LLC	$5.7B	15,696,068
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$5.4B	15,034,038
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.4B	14,853,366
MORGAN STANLEY	$4.9B	13,653,692
WELLS FARGO & COMPANY/MN	$2.6B	7,235,462

Companies Similar to AMGN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ABBV

AbbVie Inc.

AI score

Highly similar · 45 shared holders

Capital World Investors Capital Research Global Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

LLY

ELI LILLY & Co

AI score

Highly similar · 45 shared holders

Capital World Investors PRIMECAP MANAGEMENT CO/CA/Capital Research Global Investors

ABT

ABBOTT LABORATORIES

AI score

Very similar · 42 shared holders

Capital Research Global Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Capital International Investors

MMM

3M CO

AI score

Very similar · 39 shared holders

Capital World Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

MDT

Medtronic plc

AI score

Very similar · 40 shared holders

Capital Research Global Investors Capital World Investors Aristotle Capital Management, LLC

JNJ

JOHNSON & JOHNSON

AI score

Very similar · 44 shared holders

Capital World Investors Capital Research Global Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 48 shared holders

PRIMECAP MANAGEMENT CO/CA/NORDEA INVESTMENT MANAGEMENT AB Capital International Investors

SYK

STRYKER CORP

AI score

Very similar · 31 shared holders

Capital Research Global Investors NORDEA INVESTMENT MANAGEMENT AB Boston Partners

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMGN on your watchlist

Track score changes the day AMGEN INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMGN a good stock to buy?

13F Pro's AI-powered analysis of AMGEN INC (AMGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMGN are available on the AMGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AMGN is classified as a mega company.

Which hedge funds own AMGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AMGEN INC's investment landscape.